

Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I

Children's Hospital Oakland, Oakland, California, United States

Children's Hospital of Orange County, Orange, California, United States

Emory Healthcare, Decatur, Georgia, United States

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

University of Utah Hospital, Salt Lake City, Utah, United States

AGT-181 is a fusion protein containing alpha-L-Iduronidase that is intended to deliver the enzyme peripherally and to the brain, when administered intravenously. This study is a safety and dose ranging study to obtain safety and exposure data, as well as information on the biological activity of the investigational drug.